Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.75 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.75 |
| ▸ | SSTR5 | P35346 | 9/20 | 0.46 |
| ▸ | SSTR2 | P30874 | 9/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 7/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.41 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
| ▸ | LDHB | P07195 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21258440 | 0.96 | KDM1A (0.82) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL16426329 | 0.95 | KDM1A (0.81) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL23134121 | 0.92 | KDM1A (0.68) | KDM1ARCOR1SSTR5SSTR2SSTR4 | |
| SCHEMBL21474061 | 0.91 | KDM1A (0.85) | KDM1ARCOR1 | |
| SCHEMBL21504378 | 0.91 | KDM1A (0.85) | KDM1ARCOR1 | |
| SCHEMBL21504398 | 0.91 | KDM1A (0.85) | KDM1ARCOR1 | |
| SCHEMBL21504380 | 0.91 | KDM1A (0.85) | KDM1ARCOR1 | |
| SCHEMBL21474062 | 0.91 | KDM1A (0.85) | KDM1ARCOR1 | |
| SCHEMBL21504124 | 0.91 | KDM1A (0.85) | KDM1ARCOR1 | |
| SCHEMBL25645440 | 0.91 | KDM1A (0.85) | KDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210085798-A1 | IMMUNITY LINKER MOLECULES AND THEIR USE IN THE TREATMENT OF INFECTIOUS DISEASES | CENTAURI THERAPEUTICS LIMITED (GB) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085798-A1 | IMMUNITY LINKER MOLECULES AND THEIR USE IN THE TREATMENT OF INFECTIOUS DISEASES | MYD88, MAVS, TLR3 | KDM1A 3493/4885RCOR1 3743/4885SSTR5 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.